Miroslav Šašinka, Katarína Furková
Developed countries are frightened by the constant increase in the number of patients with chronic kidney disease (CKD) – incidence has exceeded 7 % of the total population. Anaemia in chronic kidney disease occurs already in the earliest stages. Its etiology is multifactorial – renal hormone erythropoietin deficiency, iron deficiency, other chronic diseases, blood losses lack of various nutrients, inflammation. In CKD iron deficiency, inflammation, mineral and bone disorders are of particular importance. In therapy we mainly use erythropoiesis-stimulating agents (ESA) and treatment of iron deficiency and more recently peginesatide, stabilizing factor induced by hypoxia, GATA-2 inhibitors and hepcidin antagonists are used.